Formulation: A solid
Formal Name: L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginylglycylglycyl-L-threonyl-L-asparaginyl-L-valyl-L-phenylalanyl-L-asparaginyl-L-alanyl-L-threonyl-L-phenylalanyl-L-α-glutamyl-L-isoleucyl-L-tryptophyl-L-histidyl-L-α-aspartylglycyl-L-α-glutamyl-L-phenylalanylglycyl-L-threonine, acetate
Purity: ≥98%
Formula Markup: C164H251N57O45 • XC2H4O2
Formula Weight: 3741,1
Shelf life (days): 1460
Notes: Tat-beclin 1 is an autophagy-inducing peptide.{22329} It is composed of the HIV-1 Tat protein transduction domain linked via a diglycine linker to an 18-amino acid peptide corresponding to residues 267-284 of beclin-1 with amino acid substitutions at positions 275, 279, and 281 to enhance hydrophobicity. Tat-beclin 1 (30 µM) binds to the beclin-1-interacting protein Golgi-associated plant pathogenesis-related protein 1 (GAPR-1) in HeLa cells and induces conversion of LC3-I to LC3-II via lipidation and autophagosome formation in MCF-7 cells. It decreases viral titers in HeLa cells infected with Sindbis virus, chikungunya, or West Nile virus when used at a concentration of 10 µM. Tat-beclin 1 (0.5-5 µM) inhibits HIV p24 antigen release and viral replication in primary human monocyte-derived macrophages (MDMs). In vivo, Tat-beclin 1 (14 mg/kg) reduces intramuscular viral titers, neonatal mortality, and paralysis and increases muscle cell autophagosome formation in chikungunya-infected neonatal mice.
English
Deutsch
